Suboxone
Suboxone® combines buprenorphine and naloxone to reduce withdrawal symptoms while protecting against misuse.
Sublocade® is a brand name, month-long injectable medicine that contains the active ingredient buprenorphine. It is used to treat adults who are dependent on opioids. In 2017, the Food and Drug Administration (FDA) approved Suboxone for treating opiate addiction.
A 2015 study conducted by Harvard University determined that buprenorphine treatment in conjunction with therapy and/or counseling at least triples the probability an individual will achieve opioid abstinence during active treatment versus counseling alone.
Sublocade® provides a steady release of medication in the body, effectively reducing cravings and withdrawal symptoms associated with opioid dependence. This helps patients manage their addiction more comfortably and maintain their daily activities without the constant struggle against cravings and discomfort.
Buprenorphine binds to the same neuroreceptors as other opioids but doesn’t produce the same high. This blocks the euphoric effects of illicit opioids, making their use less appealing to help patients avoid relapse and achieve long-term recovery.
By providing a controlled, long-acting form of medication, Sublocade® lowers the potential for misuse. The monthly injection ensures a consistent therapeutic level of medication, reducing the risk of relapse by removing the daily decision to take medication.
The once-monthly injection schedule makes it easier for patients to stay in treatment. By eliminating the need for daily dosing, reducing cravings, and mitigating withdrawal symptoms, patients can focus on other aspects of their treatment plan, like counseling.
Ready to take the first step toward recovery? Brightside uses telehealth to ensure everyone can access life-saving addiction treatment no matter where they are. Schedule your virtual visit today!
